Longeveron Inc.
Longeveron Inc. is a U.S.-based clinical-stage biotechnology company developing laromestrocel, a cell therapy platform focused on regenerative medicine and inflammatory/degenerative diseases. It also generates limited revenue from Bahamas Registry Trials and contract development/manufacturing services while it advances FDA-enabling work for its lead programs.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of laromestrocel and related clinical/regulatory activities for lead indications.
Fee-based investigational treatment administration and trial participation in The Bahamas.
Fee-for-service research, process development, manufacturing, and testing work for third parties.
Non-dilutive research funding from NIH, Alzheimer’s Association, and Maryland Stem Cell Research Fund.
Tuotteet
Raportoitu · osuus liikevaihdosta- Clinical Trial Revenue79,6 %
- Contract Manufacturing Revenue18,5 %
- Contract Manufacturing Lease Revenue1,9 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Longeveron’s direct customers are a mix of clinical trial participants, third-party biotechnology clients, and grant-making institutions that fund research. The Bahamas Registry Trials serve patients seeking access to laromestrocel in a controlled investigational setting, while contract manufacturing customers buy specialized development and manufacturing capacity. Its grant revenue comes from public and nonprofit research funders that support clinical programs with non-dilutive capital.
Patients pay to participate in the registry trial and receive laromestrocel administration in Nassau.
Buy contract development, manufacturing, stability testing, and reserved suite capacity.
Provide non-dilutive funding for clinical research programs and performance-based milestones.
Support the company’s FDA pathway through trials, CMC work, and BLA-enabling activities.
Strategia
The company is prioritizing FDA-enabling work for its lead programs, especially CMC readiness and manufacturing scale-up, while preserving cash through disciplined capital allocation. It is also pursuing non-dilutive funding and commercial partnering, particularly for the Alzheimer’s program, to extend runway and reduce financing pressure. Management has indicated a potential BLA filing in 2026 if the HLHS program succeeds.
Regulatory progress is the main value driver and determines whether laromestrocel can reach commercialization.
The company needs additional capital to fund operations and development through key milestones.
Partnering can reduce funding burden and improve development optionality for larger indications.
Maantiede
Longeveron is headquartered in the United States and conducts most of its corporate, research, and regulatory activity there. A meaningful part of its clinical revenue is tied to The Bahamas, where the Registry Trials are administered at private clinics in Nassau. The company’s commercial exposure is therefore concentrated in the U.S. for development and in The Bahamas for trial-based revenue.
Riskit
Longeveron faces high execution risk because its lead product is still investigational and depends on successful clinical, CMC, and FDA review milestones. The business also has substantial financing risk, with limited revenue, recurring losses, and a going-concern warning that makes future dilution or unfavorable financing likely. In addition, Nasdaq listing compliance and demand volatility in the Bahamas Registry Trials can affect liquidity and near-term revenue.
- Clinical and regulatory failureVaikutus: KriittinenTodennäköisyys: Korkea
Lead programs are investigational and must clear complex FDA review and BLA-enabling requirements.
Kohdistuu: HLHS and Alzheimer’s programs
- Liquidity and going-concern pressureVaikutus: KriittinenTodennäköisyys: Korkea
The company has recurring losses, limited cash runway, and needs additional funding to continue operations.
Kohdistuu: Corporate operations and development programs
- Nasdaq delisting riskVaikutus: KorkeaTodennäköisyys: Korkea
The stock has fallen below the minimum bid price requirement, which can reduce liquidity and investor access.
Kohdistuu: Class A common stock
- Revenue concentration and volatilityVaikutus: Korkea
Revenue depends on a small number of sources, including registry trials and one manufacturing customer relationship.
Kohdistuu: Bahamas Registry Trials and contract manufacturing
Kirjanpito
Harkinnanvaraiset erätManagement must estimate progress and performance obligations, which affects timing of revenue recognition.
Vaikutus: Can shift revenue between quarters and affect gross margin
Revenue is recognized when performance obligations are met, not when cash is received.
Vaikutus: Creates timing differences versus funding receipts
Cash runway estimates depend on financing timing and operating spend.
Vaikutus: Affects disclosure and investor assessment of survival risk
Personnel costs include stock-based awards, which can be significant for a development-stage biotech.
Vaikutus: Raises operating expenses without cash outflow
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Dogwood Therapeutics, Inc.
DWTX · Pharmaceutical Preparations
Capricor Therapeutics, Inc
CAPR · Pharmaceutical Preparations
Longevity Health Holdings, Inc.
XAGEW · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
LadRx Corp
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
Enliven Therapeutics, Inc.
ELVN · Pharmaceutical Preparations
Päivitetty: 24.9.2026